

University of Groningen

Early prosthetic joint infection after primary total joint arthroplasty

Löwik, Claudia Aline Maria

DOI:
[10.33612/diss.97641504](https://doi.org/10.33612/diss.97641504)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Löwik, C. A. M. (2019). *Early prosthetic joint infection after primary total joint arthroplasty: risk factors and treatment strategies*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.
<https://doi.org/10.33612/diss.97641504>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Chapter 4

A horizontal row of 12 dots, with the first 10 being light blue and the last 2 being dark blue.

Obese patients have higher rates of polymicrobial and Gram-negative early periprosthetic joint infections of the hip than non-obese patients

Claudia A.M. Löwik, Wierd P. Zijlstra, Bas A.S. Knobben, Joris J.W. Ploegmakers,
Baukje Dijkstra, Astrid J. de Vries, Greetje A. Kampinga, Glen Mithoe, Aziz Al
Moujahid, Paul C. Jutte, Marjan Wouthuyzen-Bakker, on behalf of the Northern
Infection Network Joint Arthroplasty

Published in: PLoS One 2019; 14(4): e0215035

Abstract

Background

Obese patients are more likely to develop periprosthetic joint infection (PJI) after primary total joint arthroplasty. This study compared the clinical and microbiological characteristics of non-obese, obese and severely obese patients with early PJI, in order to ultimately optimize antibiotic prophylaxis and other prevention measures for this specific patient category.

Methods

We retrospectively evaluated patients with early PJI of the hip and knee treated with debridement, antibiotics and implant retention (DAIR) between 2006 and 2016 in three Dutch hospitals. Only patients with primary arthroplasties indicated for osteoarthritis were included. Early PJI was defined as an infection that developed within 90 days after index surgery. Obesity was defined as a BMI $\geq 30 \text{ kg/m}^2$ and severe obesity as a BMI $\geq 35 \text{ kg/m}^2$.

Results

A total of 237 patients were analyzed, including 64 obese patients (27.0%) and 62 severely obese patients (26.2%). Compared with non-obese patients, obese patients had higher rates of polymicrobial infections (60.3% vs 33.3%, $p < 0.001$) with more often involvement of *Enterococcus* species (27.0% vs 11.7%, $p = 0.003$). Moreover, severely obese patients had more Gram-negative infections, especially with *Proteus* species (12.9% vs 2.3%, $p = 0.001$). These results were only found in periprosthetic hip infections, comprising Gram-negative PJIs in 34.2% of severely obese patients compared with 24.7% in obese patients and 12.7% in non-obese patients ($p = 0.018$).

Conclusion

Our results demonstrate that obese patients with early periprosthetic hip infections have higher rates of polymicrobial infections with enterococci and Gram-negative rods, which stresses the importance of improving preventive strategies in this specific patient category, by adjusting antibiotic prophylaxis regimens, improving disinfection strategies and optimizing postoperative wound care.

Introduction

Obesity is a major health concern worldwide, as obesity has nearly tripled in the last decades. Currently, 39% of adults are overweight and 13% are obese.¹ Obesity is not only associated with an increased risk of comorbidities, such as hypertension, diabetes mellitus and ischemic heart disease,² but due to early development of osteoarthritis of weight-bearing joints, obese patients are also more likely to receive joint arthroplasty.³ Implantation of joint arthroplasties may lead to postoperative complications, particularly in obese patients.⁴ The most important complication is periprosthetic joint infection (PJI), occurring in approximately 1-2% of patients receiving joint arthroplasty.⁵ PJI has a large impact on patient's quality of life and is accompanied by high health care costs. Literature indicates that the risk of PJI increases exponentially with the body mass index (BMI): i.e. severely obese patients have a four times increased risk of PJI compared with non-obese patients.^{6,7}

There are many hypotheses for the increased risk of PJI in obese patients.⁸ First of all, obese patients are prone to diminished wound healing because of increased surface tension at the surgical site and prolonged wound leakage due to bulky subcutaneous tissue.⁹ Secondly, higher glucose levels in obese patients with diabetes mellitus increase the risk of infection.¹⁰ Thirdly, the applied cefazolin dosage as antibiotic prophylaxis may not be sufficient to achieve adequate tissue concentrations in obese patients, especially in patients weighing more than 120kg or with a BMI >40kg/m².¹¹⁻¹³ Finally, obese patients have increased bacterial colonization of the skin compared with non-obese patients, particularly in the groin.^{14,15} Currently applied antibiotic prophylaxis may not provide full coverage for these microorganisms.

To optimize prevention measures for obese patients receiving primary total joint arthroplasty, we aimed to describe the clinical and microbiological characteristics of early PJI in obese and severely obese patients.

Material and methods

Study design

We retrospectively reviewed patients with early PJI of the hip and knee who were treated with debridement, antibiotics and implant retention (DAIR) in

one university hospital (University Medical Center Groningen) and two general hospitals (Martini Hospital and Medical Center Leeuwarden) between January 2006 and December 2016. PJI was diagnosed according to the diagnostic criteria defined by the Musculoskeletal Infection Society (MSIS).¹⁶ In case of a single positive culture with a highly virulent microorganism, PJI was diagnosed in consultation with the infectious diseases specialist or medical microbiologist. Early PJI was defined as an infection developed within 90 days after index surgery.¹⁷ Only patients with primary arthroplasties indicated for osteoarthritis were included. Patients who underwent arthroscopic debridement or did not meet the MSIS criteria were excluded.

The following clinical variables were collected: sex, age, BMI, comorbidities, medication, inflammatory markers and specifications of index surgery and the DAIR procedure. BMI was measured during the preoperative anesthetic screening prior to joint arthroplasty surgery. Patients were categorized according to BMI, with a cut-off value of 30kg/m² (i.e. class 1 obesity) and 35kg/m² (i.e. class 2 obesity / severe obesity).^{1,18} Early failure was defined as the need for 1) a second DAIR procedure, 2) revision arthroplasty or definitive implant removal, 3) infection-related death or 4) suppressive antimicrobial treatment, all within 60 days after initial debridement. Overall failure was defined as infection-related death or the need for implant removal at any time point after initial debridement.

The following microbiological variables were collected: number of positive cultures, type of microorganism and resistance patterns of cultured microorganisms.

Index surgery and DAIR procedure

Prior to joint arthroplasty patients performed a whole-body cleansing with chlorhexidine scrub. In case of abundant hair growth on the knee or groin region, hair was removed from the surgical site by use of a clipper. Prior to surgical incision, the skin was disinfected with a solution of povidone tincture in 75% alcohol. In case patients were allergic to povidone, the skin was disinfected by a chlorhexidine-alcohol solution. Cefazolin was administered as antibiotic prophylaxis 30 to 60 minutes prior to incision. According to local protocol, cefazolin dosage was one gram for patients <80kg and two grams for patients ≥80kg. In all patients receiving total hip arthroplasty the posterolateral approach was used. Total knee arthroplasties were inserted via the medial

parapatellar approach. The incisions were closed with staples and dressed with absorbent bandages. In case of wound leakage in the postoperative period a pressure bandage was applied.

DAIR procedure consisted of opening the wound via the pre-existing incision, excising hematoma and avital tissue and irrigating the wound thoroughly with three to six liters of saline. Modular components were exchanged and optionally gentamicin-impregnated beads or sponges were inserted into the joint cavity according to local protocol and clinical judgement of the operating orthopaedic surgeon. Multiple cultures of deep tissue and synovial fluid were obtained during debridement. Cefuroxime was started as empirical intravenous antimicrobial treatment after obtaining cultures and was adjusted according to the culture results. Intravenous antimicrobial treatment was continued for at least two weeks before switching to an oral regimen, which was continued for an additional ten weeks. Rifampin was added to the antimicrobial treatment regimen in infections caused by rifampin-susceptible staphylococci.

Statistical analysis

Categorical variables were presented in absolute frequencies and percentages. Continuous variables were expressed as mean and standard deviation (SD) or as median and interquartile range (IQR) when not normally distributed according to the Kolmogorov-Smirnov test of normality. The statistical comparison of categorical variables was performed using the Chi-square test. Parametric continuous variables were compared using the Student's t-test and one-way ANOVA. Non-parametric continuous variables were compared with the Mann-Whitney U test. Statistical significance was defined as a two-tailed $p < 0.05$. Statistical assessment was carried out with IBM SPSS Statistics (version 24.0, Chicago, USA).

Ethical Review Committee statement

The Institutional Review Boards of the University Medical Center Groningen, Martini Hospital and Medical Center Leeuwarden approved this study. Each Institutional Review Board approved a waiver for obtaining written informed consent from the participants, since this was an observational study in which the data were analyzed anonymously. The study is conducted in accordance to the ethical standards in the 1964 Declaration of Helsinki, the Medical Research Involving Human Subjects Act (WMO) and the Good Clinical Practice standard (GCP).

Results

Clinical characteristics

A total of 356 patients with early PJI of the knee or hip treated with DAIR were identified. We excluded 52 patients with revision arthroplasties and 67 patients with primary arthroplasties placed for other indications than osteoarthritis (fracture (n=62), rheumatoid arthritis (n=2) and malignancy (n=3)). A total of 237 included patients had a mean age of 71.3 years (SD 10.5, range 27-91 years) and 63.7% of patients (n=151) were female. 160 patients (67.5%) had a periprosthetic hip infection and 77 patients (32.5%) had a periprosthetic knee infection. Patients experienced a mean duration of symptoms of infection of 6.8 days (SD 5.9, range 1-21 days) before DAIR procedure. DAIR procedure was performed at a mean of 20.7 days (SD 11.7, range 7-74 days) after index surgery. The median follow-up was 1.7 years (IQR 1.0-3.3) and was similar in obese and non-obese patients (1.8 years (IQR 1.0-3.1) vs 1.5 years (IQR 1.0-3.4), $p=0.732$).

From the included cohort (n=237) a total of 126 patients (53.2%) were obese. Of these obese patients 62 were severely obese (49.2%). Non-obese, obese and severely obese patients were of similar age (72.3 years vs 70.5 years vs 69.4 years, $p=0.229$), while severely obese patients were more often of female gender than non-severely obese patients (74.2% vs 60.0%, $p=0.046$). Regarding comorbidities, both obese and severely obese patients had a higher incidence of hypertension compared with non-obese patients and non-severely obese patients respectively (69.0% vs 56.8%, $p=0.050$ and 75.8% vs 58.9%, $p=0.017$), while diabetes mellitus only had a higher incidence in severely obese patients (35.5% vs 17.1%, $p=0.003$). Regarding symptoms at initial DAIR, severely obese patients had a higher incidence of redness of the wound compared with non-severely obese patients (39.4% vs 56.5%, $p=0.020$). There was a trend towards more wound leakage in obese patients, but this difference was not statistically significant (82.0% vs 89.7%, $p=0.088$) (Table 1).

Comparing the variables of the joint replacement surgery and DAIR procedure we did not find any differences between non-obese, obese and severely obese patients (Table 1). Regarding the outcome after DAIR, rates of early failure and overall failure were comparable between non-obese, obese and severely obese patients (30.6% vs 33.3% vs 30.6%, $p=0.740$ and 9.0% vs 10.3% vs 9.7%, $p=0.961$ respectively). In the majority of patients (n=67, 88.2%) early failure was due to the need for a second DAIR, five patients (6.6%) needed

revision surgery and two patients (2.6%) started with suppressive antimicrobial treatment after initial debridement.

Table 1. Clinical characteristics of early PJs according to BMI

| Variables | | BMI <30 (n=111) | BMI ≥30 (n=126) | P value | BMI <35 (n=175) | BMI ≥35 (n=62) | P value |
|----------------------------|---------------------------------------|--------------------|--------------------|-------------|--------------------|-------------------|-------------|
| Sex | Male | 43 (38.7%) | 43 (34.1%) | .461 | 70 (40.0%) | 16 (25.8%) | .046 |
| Age in years | Mean (SD) | 72.3 (11.7) | 70.5 (9.2) | .192 | 72.0 (10.8) | 69.4 (9.3) | .098 |
| Comorbidities | Diabetes mellitus | 20 (18.0%) | 32 (25.4%) | .171 | 30 (17.1%) | 22 (35.5%) | .003 |
| | Hypertension | 63 (56.8%) | 87 (69.0%) | .050 | 103 (58.9%) | 47 (75.8%) | .017 |
| | Ischemic heart disease | 17 (15.3%) | 23 (18.3%) | .547 | 33 (18.9%) | 7 (11.3%) | .172 |
| | COPD | 17 (15.3%) | 28 (22.2%) | .176 | 30 (17.1%) | 15 (24.2%) | .224 |
| Medication | Anticoagulants | 24 (21.6%) | 24 (19.0%) | .623 | 36 (20.6%) | 12 (19.4%) | .838 |
| | Corticosteroids | 18 (16.2%) | 10 (7.9%) | .049 | 22 (12.6%) | 6 (9.7%) | .544 |
| Smoker | | 19 (18.3%) | 18 (15.0%) | .511 | 28 (17.1%) | 9 (15.0%) | .711 |
| Serum inflammatory markers | Leukocyte count, x 10 ⁹ /L | 12.3 (5.5) | 10.4 (3.8) | .002 | 11.4 (5.0) | 10.8 (3.9) | .392 |
| | CRP, mg/L | 92.9 (96.1) | 83.1 (98.9) | .439 | 86.7 (94.7) | 90.4 (106.0) | .797 |
| Symptoms | Wound leakage | 91 (82.0%) | 113 (89.7%) | .088 | 148 (84.6%) | 56 (90.3%) | .261 |
| | Redness | 44 (39.6%) | 60 (47.6%) | .217 | 69 (39.4%) | 35 (56.5%) | .020 |
| | Fever | 25 (22.5%) | 21 (16.7%) | .255 | 33 (18.9%) | 13 (21.0%) | .718 |
| Joint | Hip | 79 (71.8%) | 81 (64.8%) | .342 | 122 (70.5%) | 38 (61.3%) | .473 |
| | Knee | 32 (28.2%) | 45 (35.2%) | | 51 (29.5%) | 24 (38.7%) | |
| Cementation | No cement | 24 (21.6%) | 21 (16.7%) | .354 | 37 (21.1%) | 8 (12.9%) | .295 |
| | Cement without antibiotics | 4 (3.6%) | 2 (1.6%) | | 5 (2.9%) | 1 (1.6%) | |
| | Cement with antibiotics | 83 (74.8%) | 103 (81.7%) | | 133 (76.0%) | 53 (85.5%) | |
| Drain | No drain | 25 (22.9%) | 32 (25.6%) | .065 | 41 (23.7%) | 16 (26.2%) | .906 |
| | 1 drain | 38 (34.9%) | 58 (46.4%) | | 71 (41.0%) | 25 (41.0%) | |
| | 2 drains | 46 (42.2%) | 35 (28.0%) | | 61 (35.3%) | 20 (32.8%) | |
| Number of DAIRs | Mean (SD) | 1.28 (0.49) | 1.31 (0.48) | .632 | 1.29 (0.48) | 1.31 (0.50) | .834 |
| Exchange of components | | 29 (26.4%) | 32 (25.4%) | .866 | 49 (28.2%) | 12 (19.4%) | .174 |
| DAIR failure | Early failure | 34 (30.6%) | 42 (33.3%) | .656 | 57 (32.6%) | 19 (30.6%) | .780 |
| | Overall failure | 10 (9.0%) | 13 (10.3%) | .734 | 17 (9.7%) | 6 (9.7%) | .993 |

Bold indicates statistically significant differences. BMI: body mass index; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; DAIR: debridement, antibiotics and implant retention; SD: standard deviation.

Microbiological characteristics

Overall, early PJIs were polymicrobial in 113 patients (47.7%). Predominant microorganisms causing the infection were *Staphylococcus aureus* (44.3%), *Staphylococcus epidermidis* (34.6%), *Streptococcus* species (21.5%) and *Enterococcus* species (19.8%). Regarding polymicrobial infections, 66.4% solely involved Gram-positive microorganisms (n=75), 2.7% solely Gram-negative microorganisms (n=3), and 31.0% involved both Gram-positive and Gram-negative microorganisms (n=35). In patients with polymicrobial infections, each obtained culture was positive in 86.7% of cases (n=98). The mean number of species cultured in these polymicrobial infections was 2.64 (range 2-7), with 2 species being cultured in 56.6% (n=64), 3 species in 30.1% (n=34), 4 species in 8.0% (n=9), 5 species in 4.4% (n=5) and 7 species in 0.9% (n=1). In case of a polymicrobial infection, *Staphylococcus epidermidis* was involved in 46.0% of cases, *Staphylococcus aureus* in 41.6%, *Enterococcus* species in 38.1%, *Streptococcus* species in 29.2% and *Proteus* species in 10.6%. The most common combination of microorganisms was *Staphylococcus aureus* together with *Streptococcus* species (n=7) and *Staphylococcus epidermidis* together with *Enterococcus* species (n=6).

Obese patients had a higher rate of polymicrobial infections than non-obese patients (60.3% vs 33.3%, $p<0.001$), with higher prevalence of *Enterococcus* species (27.0% vs 11.7%, $p=0.003$). The same applies to severely obese patients compared with non-severely obese patients (polymicrobial infections in 59.7% vs 43.4%, $p=0.028$ and *Enterococcus* species in 32.2% vs 15.4%, $p=0.004$). Overall, there were no differences regarding Gram-negative microorganisms between obese and non-obese patients, but there were significantly more infections caused by *Proteus* species in severely obese patients compared with non-severely obese patients (12.9% vs 2.3%, $p=0.001$).

Analyzing patients with PJI of the hip and knee separately, we found that the higher rate of polymicrobial infections in obese patients, including *Enterococcus* species and Gram-negative microorganisms, was only significant in patients with periprosthetic hip infections (Table 2). Gram-negative rods were isolated in 34.2% of severely obese patients with hip PJI, compared with 24.7% in obese patients and 12.7% in non-obese patients ($p=0.018$). *Proteus* species were the main isolated Gram-negative microorganism, with a higher rate in severely obese patients compared with non-severely obese patients (18.4% vs 1.6%, $p<0.001$). Moreover, *Morganella morganii* was more often involved in

severely obese patients (7.9% vs 0.0%, $p=0.002$). These differences were not significant in obese patients compared with non-obese patients. Assessment of the microbiological characteristics in patients with periprosthetic knee infections only showed a significant higher rate of involvement of *Enterococcus faecium* in severely obese compared with non-severely obese patients (8.3% vs 0.0%, $p=0.037$). There were no other significant differences between non-obese, obese and severely obese patients (Table 3).

Regarding the susceptibility analyses of cefazolin and cefuroxime in Gram-negative microorganisms, results of these tests were only partially available. Microorganisms that are intrinsically resistant to cefazolin and cefuroxime (such as *Enterococcus* species, *Enterobacter cloacae*, *Proteus vulgaris* and *Morganella morganii*) are not indicated. *E. coli* was sensitive to cefazolin in all tested cases ($n=3$). *Proteus mirabilis* showed intermediate resistance to cefazolin in 33.3% ($n=3$). Regarding cefuroxime, *E. coli* ($n=6$), *Klebsiella* species ($n=1$) and *Proteus mirabilis* ($n=11$) all showed 100% sensitivity.

Discussion

This study describes the differences in clinical and microbiological characteristics of early PJI between non-obese, obese and severely obese patients. Our results demonstrated that obese and severely obese patients with periprosthetic hip infections had higher rates of polymicrobial infections with involvement of *Enterococcus* species. Moreover, severely obese patients with PJI of the hip had a higher rate of infections with Gram-negative microorganisms than non-severely obese patients. Interestingly, these results were not found in obese patients with periprosthetic knee infections, which indicates that infections of the hip and knee should be perceived as two separate entities and should therefore be approached differently. Even though the outcome after DAIR was comparable between non-obese, obese and severely obese patients, the differences in microbiological profile between obese and non-obese patients indicate that preventive measures should be adapted for hip arthroplasty surgery in obese patients.

Table 2. Isolated microorganisms during DAIR in early PILs of the hip according to BMI

| Variables | Mean (SD) | BMI <30 (n=79) | BMI ≥30 (n=81) | P value | BMI <35 (n=122) | BMI ≥35 (n=38) | P value |
|---------------------------------|-------------------------------------|----------------|----------------|-----------------|-----------------|----------------|-----------------|
| Percentage of positive cultures | | 91.4 (20.1) | 91.8 (18.5) | .917 | 90.7 (20.9) | 94.4 (12.2) | .304 |
| Polymicrobial infection | | 27 (34.2%) | 55 (67.9%) | <.001 | 56 (45.9%) | 26 (68.4%) | .015 |
| Gram-positive microorganisms | | 76 (96.2%) | 78 (96.3%) | .975 | 117 (95.9%) | 37 (97.4%) | .678 |
| | <i>Staphylococcus aureus</i> | 33 (41.8%) | 32 (39.5%) | .770 | 51 (41.8%) | 14 (36.8%) | .587 |
| | <i>Staphylococcus epidermidis</i> | 25 (31.6%) | 35 (43.2%) | .131 | 43 (35.2%) | 17 (44.7%) | .291 |
| | <i>Corynebacterium</i> species | 7 (8.9%) | 20 (24.7%) | .008 | 22 (18.0%) | 5 (13.2%) | .484 |
| | <i>Enterococcus</i> species | 10 (12.7%) | 24 (29.6%) | .009 | 20 (16.4%) | 14 (36.8%) | .007 |
| | <i>Enterococcus faecalis</i> | 7 (8.9%) | 20 (24.7%) | .008 | 16 (13.1%) | 11 (28.9%) | .023 |
| | <i>Enterococcus faecium</i> | 1 (1.3%) | 0 (0.0%) | .310 | 1 (0.8%) | 0 (0.0%) | .576 |
| | <i>Streptococcus</i> species | 20 (25.3%) | 16 (19.8%) | .399 | 32 (26.2%) | 4 (10.5%) | .043 |
| | Other gram-positives ^a | 3 (3.8%) | 3 (3.7%) | .975 | 4 (3.3%) | 2 (5.3%) | .574 |
| Gram-negative microorganisms | | 10 (12.7%) | 20 (24.7%) | .051 | 17 (13.9%) | 13 (34.2%) | .005 |
| <i>Enterobacteriaceae</i> | | 2 (2.5%) | 3 (3.7%) | .670 | 3 (2.5%) | 2 (5.3%) | .386 |
| | <i>Escherichia coli</i> | 2 (2.5%) | 3 (3.7%) | .670 | 3 (2.5%) | 2 (5.3%) | .386 |
| | <i>Enterobacter cloacae</i> | 2 (2.5%) | 7 (8.6%) | .094 | 2 (1.6%) | 7 (18.4%) | <.001 |
| | <i>Proteus</i> species ^b | 1 (1.3%) | 0 (0.0%) | .310 | 1 (0.8%) | 0 (0.0%) | .576 |
| | <i>Klebsiella</i> species | 0 (0.0%) | 3 (3.7%) | .084 | 0 (0.0%) | 3 (7.9%) | .002 |
| Non-fermenters | | 3 (3.8%) | 3 (3.7%) | .975 | 5 (4.1%) | 1 (2.6%) | .678 |
| | <i>Morganella morganii</i> | 1 (1.3%) | 2 (2.5%) | .575 | 2 (1.6%) | 1 (2.6%) | .694 |
| | <i>Pseudomonas</i> species | 1 (1.3%) | 4 (4.9%) | .724 | 4 (3.3%) | 3 (7.9%) | .224 |
| | <i>Acinetobacter</i> species | 3 (3.8%) | 1 (1.2%) | .322 | 0 (0.0%) | 1 (2.6%) | .072 |
| Anaerobe microorganisms | | 0 (0.0%) | 1 (1.2%) | | | | |
| <i>Candida</i> species | | | | | | | |

Bold indicates statistically significant differences. BMI: body mass index; SD: standard deviation.

^a *Micrococcus luteus* (n=2), *Microbacterium flavescens* (n=1), *Dolosigranulorum pigrum* (n=1), *Kocuria* species (n=1), *Rothia mucilaginosa* (n=1).

^b 8/9 *Proteus* species that were isolated were *Proteus mirabilis*, 1/9 was *Proteus vulgaris*.

Table 3. Isolated microorganisms during DAIR in early PJIs of the knee according to BMI

| Variables | Mean (SD) | BMI <30 (n=31) | BMI ≥30 (n=44) | P value | BMI <35 (n=51) | BMI ≥35 (n=24) | P value |
|-----------------------------------|-----------|----------------|----------------|---------|----------------|----------------|---------|
| Percentage of positive cultures | | 85.3 (30.1) | 91.3 (22.0) | .318 | 86.5 (28.3) | 93.8 (18.3) | .251 |
| Polymicrobial infection | | 9 (29.0%) | 20 (45.5%) | .150 | 18 (35.3%) | 11 (45.8%) | .382 |
| Gram-positive microorganisms | | | | | | | |
| <i>Staphylococcus aureus</i> | | 27 (87.1%) | 42 (95.5%) | .189 | 46 (90.2%) | 23 (95.8%) | .401 |
| <i>Staphylococcus epidermidis</i> | | 15 (48.4%) | 24 (54.5%) | .599 | 26 (51.0%) | 13 (54.2%) | .797 |
| <i>Corynebacterium</i> species | | 8 (25.8%) | 14 (31.8%) | .573 | 15 (25.5%) | 9 (37.5%) | .287 |
| <i>Enterococcus</i> species | | 3 (9.7%) | 5 (11.4%) | .816 | 5 (9.8%) | 3 (12.5%) | .724 |
| <i>Enterococcus faecalis</i> | | 3 (9.7%) | 10 (22.7%) | .142 | 7 (13.7%) | 6 (25.0%) | .229 |
| <i>Enterococcus faecium</i> | | 2 (6.5%) | 5 (11.4%) | .471 | 5 (9.8%) | 2 (8.3%) | .838 |
| <i>Streptococcus</i> species | | 0 (0.0%) | 2 (4.5%) | .229 | 0 (0.0%) | 2 (8.3%) | .037 |
| Other gram-positives ^a | | 6 (19.4%) | 9 (20.5%) | .907 | 12 (23.5%) | 3 (12.5%) | .265 |
| Gram-negative microorganisms | | 1 (3.2%) | 2 (4.5%) | .774 | 2 (3.9%) | 1 (4.2%) | .960 |
| <i>Enterobacteriaceae</i> | | | | | | | |
| <i>Escherichia coli</i> | | 4 (12.9%) | 7 (15.9%) | .717 | 8 (15.7%) | 3 (12.5%) | .716 |
| <i>Enterobacter cloacae</i> | | 0 (0.0%) | 1 (2.3%) | .398 | 1 (2.0%) | 0 (0.0%) | .490 |
| <i>Proteus mirabilis</i> | | 2 (6.5%) | 2 (4.5%) | .718 | 3 (5.9%) | 1 (4.2%) | .758 |
| <i>Klebsiella</i> species | | 1 (3.2%) | 2 (4.5%) | .774 | 2 (3.9%) | 1 (4.2%) | .960 |
| <i>Morganella morganii</i> | | 0 (0.0%) | 0 (0.0%) | 1.000 | 0 (0.0%) | 0 (0.0%) | 1.000 |
| <i>Pseudomonas</i> species | | 0 (0.0%) | 0 (0.0%) | 1.000 | 0 (0.0%) | 0 (0.0%) | 1.000 |
| <i>Acinetobacter</i> species | | 1 (3.2%) | 1 (2.3%) | .801 | 1 (2.0%) | 1 (4.2%) | .580 |
| Anaerobe microorganisms | | 0 (0.0%) | 1 (2.3%) | .398 | 1 (2.0%) | 0 (0.0%) | .490 |
| <i>Candida</i> species | | 0 (0.0%) | 0 (0.0%) | 1.000 | 0 (0.0%) | 0 (0.0%) | 1.000 |

Bold indicates statistically significant differences. BMI: body mass index; SD: standard deviation.

^a *Granulicatella adiacens* (n=2), *Staphylococcus lugdunensis* (n=1).

The concept of abundant colonization with multiple microorganisms in the hip region^{14,15} is expected to mainly apply to direct anterior incisions, as previously described in literature.^{19,20} Interestingly, in our cohort obese patients showed abundant colonization with multiple microorganisms as well, even though posterolateral incisions were used for implantation of the hip arthroplasties. Contamination of the wound can occur primarily during surgery or secondarily in the postoperative period. Primary contamination may occur if inadequate antibiotic prophylaxis is applied (either by insufficient dosage or inadequate type of antibiotics) or if the hip region is not thoroughly disinfected. The latter may be prevented by more thorough disinfection of the hip region, for example by using chlorhexidine-alcohol as a local disinfectant. Even though there are no large trials comparing chlorhexidine-alcohol with povidone tincture in 75% alcohol, it is proven that chlorhexidine-alcohol is more effective than povidone-iodine in reducing postoperative infections.²¹ This superior protection is mainly attributed to a reduction in Gram-positive skin flora by rapid action and persistent activity despite exposure to bodily fluids.²¹ Nevertheless, there was a high number of polymicrobial infections in our cohort, caused by microorganisms susceptible to the local disinfectant as well as the antimicrobial prophylaxis. This may indicate that either the antibiotic dosage was too low or that a significant proportion of PJIs developed due to secondary contamination in the postoperative period, maybe due to prolonged wound leakage, via the retrograde pathway.²² Although our data showed a trend towards a higher rate of wound leakage in obese patients, this difference was not statistically significant. To prevent secondary contamination, it is important to provide adequate wound care with sterile absorbent dressings and pressure bandages.²³ Therefore, obese patients should be evaluated more extensively after joint arthroplasty, to detect wound complications and provide adequate wound care at an early time point.

A different option for improving preventive measures in obese patients receiving total hip arthroplasty is to increase the dosage of cefazolin, especially since previous studies showed that the currently applied cefazolin dosage as antibiotic prophylaxis may not be sufficient to achieve adequate tissue concentrations in obese patients.¹¹⁻¹³ Another reason to increase the dosage of cefazolin is the higher rate of infections caused by *Proteus* species in obese patients in our cohort, since *Proteus* species have a higher minimum inhibitory concentration for cefazolin than other Enterobacteriaceae.²⁴ Recently the Dutch

guideline for antibiotic prophylaxis was adjusted, in which it is now advised to administer three grams of cefazolin in patients with a BMI $>40 \text{ kg/m}^2$,²⁵ although our results suggest that this higher dosage may also be beneficial for patients with a BMI $>35 \text{ kg/m}^2$.

Another option is to broaden the antibiotic prophylaxis during total hip arthroplasty surgery in obese patients, especially since cefazolin does not cover for *Enterococcus* species and most of the Gram-negative rods.²⁶ Broadening the prophylaxis to cefuroxime combined with vancomycin or teicoplanin may be an option. Previous studies compared the efficacy of various antibiotic prophylaxis regimens in reducing infection rates after joint arthroplasty, mostly by adding an antibiotic agent with a broader Gram-positive spectrum (such as a glycopeptide). Two studies compared the efficacy of cefazolin with a combined regimen of cefazolin and vancomycin.²⁷⁻²⁸ Liu et al. found a reduction in infections in the combined regimen group,²⁷ while Sewick et al. did not detect a difference between the regimens.²⁸ Other studies compared the use of cefuroxime and a combined regimen of cefuroxime and teicoplanin and found a reduced infection rate in the combined treatment group.^{29,30} The higher efficacy of the combined regimens in these studies was mainly based on a reduction in infections caused by methicillin-resistant *Staphylococcus aureus*.

Tornero et al. studied the efficacy of dual prophylaxis (cefuroxime plus teicoplanin) and found a reduction in PJI rate solely in obese patients when adding teicoplanin to the antimicrobial regimen.³⁰ This reduction was mainly observed for PJI due to methicillin-susceptible *Staphylococcus aureus*, which supports the hypothesis that the dosage of antimicrobial prophylaxis may be insufficient in obese patients, since methicillin-susceptible *Staphylococcus aureus* should be fully covered by cefuroxime. A randomized controlled trial is needed to provide conclusive scientific evidence regarding the most effective antibiotic prophylaxis regimen for obese patients. This randomized trial should compare different antibiotic regimens and should show whether the absolute percentage of PJIs indeed decreases when adapting the antibiotic prophylaxis regimen in obese patients receiving total hip arthroplasty.

There are several limitations to our study. First of all, we merely included patients with early PJI treated with DAIR. We did not include chronic infections, which could have provided additional insights, as these patients may have different microbiological profiles. We did not collect data on the total number of joint arthroplasties implanted in the participating hospitals during the

study period. Therefore, we do not know the exact incidence of PJI in our cohort. However, previous studies clearly demonstrated a higher rate of PJI in obese patients,^{6,7} and therefore, it is likely that implementing the proposed prevention strategies will result in an absolute reduction of PJIs in the obese population. A second limitation is the retrospective design of this study. However, due to thorough recording of clinical and microbiological findings in the electronic patient files of patients with PJI there were few missing variables, by which the results are representative for the included patients. Finally, we did not collect data on the exact disinfective agent that has been applied prior to surgery, because we could not reliably collect the allergies of included patients. However, in consultation with the orthopaedic surgeons in the participating hospitals we are confident that the disinfection procedure has been carried out correctly in each patient, whether with a povidone-alcohol solution or with a chlorhexidine-alcohol solution.

A strength of this study is that we were able to select a large homogenous group of patients with early PJI. Our initial statistical analyses showed that non-obese patients had a significantly higher rate of arthroplasties indicated for fracture than obese patients (27.6% vs 10.6%, $p < 0.001$, S1 File). Since literature indicates that fracture-related PJIs have a lower rate of Gram-negative infections and a higher failure rate compared with primary PJIs,³¹ we decided to only analyze patients with primary arthroplasties indicated for osteoarthritis.

In conclusion, obese and severely obese patients with early periprosthetic hip infections have higher rates of polymicrobial infections with involvement of enterococci and Gram-negative rods, which emphasizes the importance of improving preventive strategies in this specific patient category.

References

1. World Health Organization. Obesity and overweight. Report 2018. www.who.int.
2. Pi-Sunyer X. The medical risks of obesity. *Postgrad Med* 2009; 121(6): 21-33.
3. Bourne R, Mukhi S, Zhu N, Keresteci M, Marin M. Role of obesity on the risk for total hip or knee arthroplasty. *Clin Orthop Relat Res* 2007; 465: 185-8.
4. Arsoy D, Woodcock JA, Lewallen Dg, Trousdale RT. Outcomes and complications following total hip arthroplasty in the super-obese patient, BMI >50. *J Arthroplasty* 2014; 29(10): 1899-905.
5. Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J. Prosthetic joint infection risk after TKA in the medicare population. *Clin Orthop Relat Res* 2010; 468(1): 52-6.
6. Chen J, Cui Y, Li X, Miao X, Wen Z, Xue Y, et al. Risk factors for deep infection after total knee arthroplasty: a meta-analysis. *Arch Orthop Trauma Surg* 2013; 133(5): 675-87.
7. Smith JO, Frampton CMA, Hooper GJ, Young SW. The impact of patient and surgical factors on the rate of postoperative infection after total hip arthroplasty – a New Zealand joint registry study. *J Arthroplasty* 2018; 33(6): 1884-90.
8. Eka A, Chen AF. Patient-related medical risk factors for periprosthetic joint infection of the hip and knee. *Ann Transl Med* 2015; 3(16): 233.
9. Patel VP, Walsh M, Sehgal B, Preston C, DeWal H, Di Cesare PE. Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. *J Bone Joint Surg Am* 2007; 89(1): 33-8.
10. Dowse MM, Choong PF. Obese diabetic patients are at substantial risk for deep infection after primary TKA. *Clin Orthop Relat Res* 2009; 467(6): 1577-81.
11. Grupper M, Kuti JL, Swank ML, Maggio L, Hughes BL, Nicolau DP. Population pharmacokinetics of cefazolin in serum and adipose tissue from overweight and obese women undergoing cesarean delivery. *J Clin Pharmacol* 2017; 57(6): 712-9.
12. Kram JJF, Greer DM, Cabrera O, Bulage R, Forgie MM, Siddiqui DS. Does current cefazolin dosing achieve adequate tissue and blood concentrations in obese women undergoing cesarean section? *Eur J Obstet Gynecol Biol* 2017; 210: 334-41.
13. Rondon AJ, Kheir MM, Tan TL, Shohat N, Greenky MR, Parvizi J. Cefazolin prophylaxis for total joint arthroplasty: obese patients are frequently underdosed and at increased risk for periprosthetic joint infection. *J Arthroplasty* 2018; 33(11): 3551-4.
14. Boni L, Kuster SP, Bartik B, Zbinden R, Zingg PO, Achermann Y. Association of *Cutibacterium avidum* colonization in the groin with obesity: a potential risk factor for hip periprosthetic joint infection. *Clin Infect Dis* 2018; 67(12): 1878-82.
15. Font-Viczarra L, Tornero E, Bori G, Bosch J, Mensa J, Soriano A. Relationship between intraoperative cultures during hip arthroplasty, obesity and the risk of early prosthetic joint infection: a prospective study of 428 patients. *Int J Artif Organs* 2011; 34(9): 870-5.
16. Parvizi J, Zmistowski B, Berbari EF, Bauer TW, Springer BD, Della Valle CJ, et al. New definition for periprosthetic joint infection: from the workgroup of the musculoskeletal infection society. *Clin Orthop Relat Res* 2011; 469(11): 2992-4.
17. Barrett L, Atkins B. The clinical presentation of prosthetic joint infection. *J Antimicrob Chemother* 2014; 69(Suppl 1): 25-8.
18. Centers for Disease Control and Prevention. Defining adult overweight and obesity. Report 2016. www.cdc.gov.
19. Hodgkiss-Harlow KD, Bandyk DF. Antibiotic therapy of aortic graft infection: treatment and prevention recommendations. *Semin Vasc Surg* 2011; 24(4): 191-8.
20. Ilchmann T, Zimmerli W, Bolliger L, Graber P, Clauss M. Risk of infection in primary, elective total hip arthroplasty with direct anterior approach or lateral transgluteal approach: a prospective cohort study of 1104 hips. *BMC Musculoskelet Disord* 2016; 17(1): 471.
21. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. *N Engl J Med* 2010; 362(1): 18-26.

22. Weiss AP, Krackow KA. Persistent wound drainage after primary total knee arthroplasty. *J Arthroplasty* 1993; 8(3): 285-9.
23. Jaber FM, Parvizi J, Haytmanek CT, Joshi A, Purtill J. Procrastination of wound drainage and malnutrition affect the outcome of joint arthroplasty. *Clin Orthop Relat Res* 2008; 466(6): 1368-71.
24. European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website. www.eucast.org.
25. Bauer M, van de Garde E, van Kasteren M, Prins J, Vos M. SWAB-richtlijn: perioperatieve profylaxe. www.swab.nl.
26. Turnidge JD. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints. *Clin Infect Dis* 2011; 52(7): 917-24.
27. Liu C, Kakis A, Nicols A, Ries MD, Vail TP, Bozic KJ. Targeted use of vancomycin as perioperative prophylaxis reduces periprosthetic joint infection in revision TKA. *Clin Orthop Relat Res* 2014; 472(1): 227-31.
28. Sewick A, Makani A, Wu C, O'Donnell J, Baldwin KD, Lee GC. Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty? *Clin Orthop Relat Res* 2012; 470(10): 2702-7.
29. Soriano A, Popescu D, García-Ramiro S, Bori G, Martínez-Pastor JC, Balasso V, et al. Usefulness of teicoplanin for preventing methicillin-resistant *Staphylococcus aureus* infections in orthopedic surgery. *Eur J Clin Microbiol Infect Dis* 2006; 25(1): 35-8.
30. Tornero E, Garcí-Ramiro S, Martínez-Pastor JC, Bori G, Bosch J, Morata L, et al. Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty. *Antimicrob Agents Chemother* 2015; 59(2): 831-7.
31. De Vries LMA, Neve WC, Steens J. Prosthesis retention after an infected hip prosthesis: hip fractures versus primary total hip prosthesis, data from 1998-2015. *J Bone Joint Infect* 2018; 3(3): 118-22.

